Nahdi Medical Company · TADAWUL:4164
Nahdi Medical — FY2025 Earnings Presentation
23 slides from Nahdi Medical's earnings presentation, 2025
Slide 1: Investor Presentation Nahdi Medical Company FY 2025
INVESTOR PRESENTATION Nahdi Medical Company FY 2025
Slide 2: Financial Highlights
Financial Highlights
Slide 3: FY 2025 Financial Highlights
FY 2025 Financial Highlights (% of revenue) Q4 2025 % Change Q4 2024 Revenue 2.59B 9.6% 2.36B RESILIENT FINANCIAL Gross Profit 955M(36.9%) 9.1% 875M (37.0%) PERFORMANCE Operating Profit 208M(8.0%) 8.3% 192M (8.1%) Net Profit 176M (6.8%) 11.4% 158M (6.7%) EBITDA 415M (16.0%) 7.7% 385M (16.3%) (% of r
Slide 4: Solid Revenue Growth Across Businesses & Categories
Solid Revenue Growth Across Businesses & Categories Pharmacies 1,120 1,181 1,222 Revenue grew by 8.1% YoY in FY 2025, increasing by 767 million, Clinics 6 10 14 driven by strong growth momentum across all business 8.1% segments M 8,714 9,446 10,213 Retail business rose by 6.2% fueled by the continue
Slide 5: Diversified Sales Channel Growth Driving Top-Line Acceleration
Diversified Sales Channel Growth Driving Top- 12,000 Line Acceleration M +75.3% +35.5% +8.1% +6.2% 150 49 10,213 566 10,000 9,446 The Retail business continued to lead the overall growth 8,000 Contribution from Healthcare and UAE business increased to 5% up from 3% same period last 6,000 97% 95% yea
Slide 6: Best in Class Operating Profit Margin
Best in Class Operating Profit Margin Solid Operating Profit Growth Despite Operating Margin Ongoing Investments 11.0% 9.2% 9.1% The gross margin stood at 37.3% despite the ongoing investments to 6.1% support top-line growth and M accelerated growth in the Healthcare 961 873 927 and online businesse
Slide 7: Attractive Net Profit Profile
Net Profit/ Revenue Attractive Net Profit Profile 10.2% 8.7% 8.1% Net profit reached 831 million, 1.2% 1.2% increase, reflecting an 8.1% margin M 893 821 831 Items below operating profit reflected a net increase in expenses of 43 million, primarily driven by higher financial charges and lease liabil
Slide 8: Guidance
Guidance 2025 Guidance 2025 Actuals Total revenue Revenue growth 8.1% Growth (6% - 8%) ✓ Updated EPS* EPS Expected to grow annually at (1% - 2%) 1.2% ✓ Capex Capex (~4%) 4.1% ✓ Expected to Dividend Policy continue at 88% ✓ (70% - 80%) Growth to be funded Capital Structure organically Zero Debt ✓ Not
Slide 9: Strategy & Operational Review
Strategy & Operational Review
Slide 10: Our Passion for People
Our Passion for People Always Delivers Value to Our Guests 37.5 % Nationalization No. 1 1300+ national pharmacists Ranked 2nd among Saudi Arabia, Ranked 3rd among Middle East The Best Workplaces for Women Nahdi Medical Company | FY 2025 EARNINGS CALL
Slide 11: Nahdi: Guest Satisfaction - the Cornerstone of our strategy
Nahdi: Guest Satisfaction - the Cornerstone of our strategy Stronger Brand Equity YoY Nielsen Store Equity Index ** 67% of revenue Q4 2024 Q4 2025 generated from Nahdi “Nuhdeek” Guests * As FY 2025 6.9 6.9 Strong 3.4 3.4 91 NPS As FY 2025 Moderate 1.3 1.0 0.8 0.9 0.7 0.6 0.3 0.3 Weak Source: Company
Slide 12: Driving Healthcare Leadership and CSR Impact
Won in Q4 2025 Driving Healthcare Leadership and CSR Impact H.E. the Minister of MOH presents H.E. the Minister of HRSD presents Nahdi Nahdi’s CEO with the with the Top Healtcare Leaders Best Practices in CSR Award in the Middle East Award Gold category
Slide 13: Prestigious Awards Across Multiple Categories
Prestigious Awards Across Multiple Categories won in 2025
Slide 14: Strategic Initiatives
Strategic Initiatives
Slide 15: Digital Acceleration: Seamless Experiences to Fuel Nahdi's 2025 Growth
Digital Acceleration: Seamless Experiences to Fuel Nahdi’s 2025 Growth 30 Min Delivery Quick commerce with Realtime tracking Record Online Revenue Best Customer FY 2025 Crossing Feedback 2.5BN Solution Utilizing GenAI Award Contribution 25.8% vs 21.7% FY 2024 Ranked among the top companies in the M
Slide 16: Serve our community, expand our healthcare guest reach
As the market leader with a strong purpose, it provides us the opportunity to serve our community unique opportunity to expand our healthcare guest reach NPS 91 Transaction Q4 2.3M Cross selling ~ 10%
Slide 17: Nahdi's Private Label Powerhouse; Delivering Growth & Guest Loyalty
Nahdi’s Private Label Powerhouse; Delivering Growth & Guest Loyalty Private Label contribution 17.4% vs 13.4% FY 2024 Robust product expansion: Launched 6,625 SKUs during the year with a strategic focus on Beauty & Medicine
Slide 18: Nahdi's Leap: Advancing National Healthcare Leadership
Nahdi’s Leap: Advancing National Healthcare Leadership Opened 4 NahdiCare polyclinics in Riyadh and Abha, reaching a total of 14 polyclinics across 9 cities in KSA NahdiCare business demonstrated another year of exceptional growth, Revenue +75% vs FY 2024 Mature polyclinic delivered double digit bot
Slide 19: Nahdi's Strategic Expansion in UAE; A Robust Platform for Regional Growth
Broad geographic coverage Nahdi's Strategic with presence in all major Emirates, which Expansion in UAE; strengthens our reach A Robust Platform for Regional Growth UAE NPS at 91 Established Best-in-class distribution center in Dubai Investment Park (DIP) Strong growth in Revenue SAR 190M, +35.5% an
Slide 20: Introducing Our 2030 Strategy
Introducing Our 2030 Strategy B E A T S Guests @ Best-in-class Elevated Accelerate Tech-enabled Seeding the H eart retail offering omnichannel omnihealth tomorrow for the future of all we do experience Nahdi Medical Company | FY 2025 EARNINGS CALL 25
Slide 21: 2026 Guidance
Guidance 2026 Guidance Total revenue Growth 6% - 8% EPS Growth 1% - 2% Capex ~4% Dividend Policy 75% - 85% Note: 2026 guidance is for full fiscal year
Slide 22: We exist to add beats to the lives of our GUESTS
We exist to add beats to the lives of our GUESTS 2 Million new unique Guests Nahdi Medical Company | FY 2025 EARNINGS CALL 27
Slide 23: Thank You
Thank You Investor Relations Department Contacts: Website: https://investors.nahdi.sa/ Email: IR@nahdi.sa Phone: +966 556 315 822 Nahdi Medical Company | FY 2025 EARNINGS CALL 28